Plasma level monitoring of oxcarbazepine in epileptic patients

被引:36
作者
González-Esquivel, DF
Ortega-Gavilán, M
Alcántara-López, G
Jung-Cook, H
机构
[1] Inst Nacl Neurol & Neurocirug, Lab Neuropsicofarmacol, Mexico City 14269, DF, Mexico
[2] Univ Nacl Autonoma Mexico, Fac Quim, Dept Farmacia, Div Estudios Posgrado, Mexico City 04510, DF, Mexico
来源
ARCHIVES OF MEDICAL RESEARCH | 2000年 / 31卷 / 02期
关键词
oxcarbazepine; antiepileptic drugs; drug monitoring;
D O I
10.1016/S0188-4409(00)00056-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background. Despite the wide use of oxcarbazepine (OXC) there is little data concerning the usefulness of plasma level monitoring with this drug in Mexican patients with epilepsy. The purpose of the present study was to determine whether OXC levels correlate with dose, age, weight, or drugs used concomitantly. Methods. Plasma levels of the antiepileptic drug OXC were evaluated ill 214 patients with epilepsy. In each patient, plasma MHD (10-hydroxycarbazepine, the main metabolite of OXC) concentration was determined. Additionally, plasma protein binding was determined in 30 patients and affinity to red blood cells (RBCs) was evaluated in 50 patients. Results. Our results showed that the mean plasma level of MHD was 15.34 mu g/mL, mean protein binding ranged between 30-40%, and the mean RBC concentration was 18.38 mu g/mL. A relationship between dose/weight and plasma concentration was found (r = 0.5149, p <0.001). In addition, a linear relationship between plasma and RBC concentration was established (r = 0.8806, p <0.0001). Conclusion. These results suggest that for OXC, routine RBC concentrations are not necessary to make drug adjustments. (C) 2000 IMSS. Published by Elsevier Science Inc.
引用
收藏
页码:202 / 205
页数:4
相关论文
共 11 条
[1]   OXCARBAZEPINE - PHARMACOKINETIC INTERACTIONS AND THEIR CLINICAL RELEVANCE [J].
BARUZZI, A ;
ALBANI, F ;
RIVA, R .
EPILEPSIA, 1994, 35 :S14-S19
[2]  
Faigle J W, 1990, Behav Neurol, V3, P21, DOI 10.3233/BEN-1990-31S104
[3]   New drugs for the treatment of epilepsy [J].
Fraser, AD .
CLINICAL BIOCHEMISTRY, 1996, 29 (02) :97-110
[4]  
FRIIS ML, 1993, ACTA NEUROL SCAND, V56, P603
[5]   OXCARBAZEPINE (GP-47.680) - A POSSIBLE ALTERNATIVE TO CARBAMAZEPINE [J].
HOUTKOOPER, MA ;
LAMMERTSMA, A ;
MEYER, JWA ;
GOEDHART, DM ;
MEINARDI, H ;
VANOORSCHOT, CAEH ;
BLOM, GF ;
HOPPENER, RJEA ;
HULSMAN, JARJ .
EPILEPSIA, 1987, 28 (06) :693-698
[6]  
Jung H, 1997, BIOPHARM DRUG DISPOS, V18, P17
[7]   USE OF SALIVA FOR MONITORING OXCARBAZEPINE THERAPY IN EPILEPTIC PATIENTS [J].
KLITGAARD, NA ;
KRISTENSEN, O .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (01) :91-94
[8]   PHARMACOKINETICS OF 10-OH-CARBAZEPINE, THE MAIN METABOLITE OF THE ANTI-EPILEPTIC OXCARBAZEPINE, FROM SERUM AND SALIVA CONCENTRATIONS [J].
KRISTENSEN, O ;
KLITGAARD, NA ;
JONSSON, B ;
SINDRUP, S .
ACTA NEUROLOGICA SCANDINAVICA, 1983, 68 (03) :145-150
[9]   SIMULTANEOUS HPLC DETERMINATION OF OXCARBAZEPINE, CARBAMAZEPINE AND THEIR METABOLITES IN SERUM [J].
KUMPS, A .
JOURNAL OF LIQUID CHROMATOGRAPHY, 1984, 7 (06) :1235-1241
[10]   LACK OF ENZYME-INDUCTION WITH OXCARBAZEPINE (600 MG DAILY) IN HEALTHY-SUBJECTS [J].
LARKIN, JG ;
MCKEE, PJW ;
FORREST, G ;
BEASTALL, GH ;
PARK, BK ;
LOWRIE, JI ;
LLOYD, P ;
BRODIE, MJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (01) :65-71